about
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesHCV-HIV coinfected pregnant women: data from a multicentre study in Italy.Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy.Evolving treatment implementation among HIV-infected pregnant women and their partners: results from a national surveillance study in Italy, 2001-2015Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced diseaseEffectiveness of a prevention of mother-to-child HIV transmission programme in an urban hospital in AngolaRate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.Pregnancy outcomes in women with advanced HIV infection in Italy.Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral TreatmentEvolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfectionUsefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1-infected subjects: comparison with dual X-ray absorptiometryHIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy.Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes.Pregnant with HIV before age 25: data from a large national study in Italy, 2001-2016.Rate, correlates and outcomes of repeat pregnancy in HIV-infected women.Impact of introducing subsidized combination treatment with artemether-lumefantrine on sales of anti-malarial monotherapies: a survey of private sector pharmacies in Huambo, Angola.Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series.HBV coinfection is associated with reduced CD4 response to antiretroviral treatment in pregnancy.Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants.Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization.Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1.HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.Tuberculosis case finding with combined rapid point of care assays (Xpert® MTB/RIF and LAM) in HIV-positive individuals starting antiretroviral treatment in Mozambique.Relationship between health-related quality of life measures and high HIV viral load in HIV-infected triple-class-experienced patients.Rate, predictors, and consequences of late antenatal booking in a national cohort study of pregnant women with HIV in Italy.Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers.Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study.Percentage and determinants of missed HIV testing in pregnancy: a survey of women delivering in the Lazio region, Italy.Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.Pregnancy outcomes in HIV-infected women of advanced maternal age.Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011.Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.Effect of HCV infection on glucose metabolism in pregnant women with HIV receiving HAART.Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.Plasma lipid profile in pregnant women with HIV receiving nevirapine.
P50
Q28344476-01C62CD1-BF35-4AE1-9299-4678D5888351Q31011972-9F537E5E-5E1B-4F15-810E-8F63EF86C829Q31033395-DCEC082D-2CAE-4AA8-B77A-9C3DB9699CDFQ33718592-667008F2-5569-47CE-8FDB-00B0CD10643FQ34100037-474FA12D-E403-4D67-82BE-8DCE935E46E7Q34257477-8630C395-F9AA-497A-85AD-EDCB8E17D456Q34869426-22070FFD-9B5B-46CC-97B9-85CE62A4E160Q35445035-89557065-EBF7-4FBD-8FAF-E0A9EC44DCBDQ35827743-73759CAF-3CFB-411A-B6BB-5E78B07F81D8Q35861475-E23C24E1-5C3A-4B84-AE2D-D93D51BFBA5AQ35953203-7DF5E184-5595-474B-9795-E2D0678A8E9FQ36467243-C3BCEAFC-4E68-46AC-B2F5-0DB7F3471B87Q36981208-6C59944E-0FA1-407F-8356-957AC9AA948DQ38380240-415F8C58-BDF3-40B8-BA80-B9D882355858Q38440876-17786A7F-DD71-4930-91C0-CA5C2F937119Q38450147-9057ADCF-6A8A-474D-8106-4E15EFA38920Q38676975-B685BF65-5694-4588-BDB5-7502DCF14387Q39078742-C8CD1340-8756-4886-91EB-C00ED9607A99Q39179328-65ECB88B-2A6B-46DF-ABFA-A015D2D5C82EQ39520236-C5CBFB25-241F-43F0-8CB3-C6C384A95E81Q39672296-DA8D3373-B616-44AB-88E0-25FE4E9FB504Q40379966-F181FA80-23A6-4D1A-B19A-A6F477BBB963Q40833730-6A810735-279B-4A6C-8591-6AB527726A2FQ40867191-A4115B46-0EF7-462E-9A6E-EED5BE0A3D7BQ40944025-8A9DA1D7-0D13-495F-B940-7E6D4E059300Q40998601-610C4966-2E06-458B-A423-BDAC87335BA6Q41918711-8C32E5DF-CE19-44AC-B14D-4ACCACA24A77Q41922196-1F084768-6399-4B92-B2D6-2FF6ED80B68DQ42198827-E59EBFF1-D29B-460C-82CB-BEC374418770Q42209715-368FF4A7-3856-4599-BB9B-D631D462057DQ42219111-EAA6C478-A018-4C35-9DC7-4AF0C7A3AA32Q42235471-08FE5B00-D754-4A54-8541-A472AB28319BQ42239100-9F720542-8FC1-42BA-9550-9ACBC3A082E0Q42246779-DAE6D689-60C6-44C1-9BAA-71267BBA700EQ42255965-89A476C6-3894-46E6-A0C5-FB1C21F7F968Q42260917-D8676AAA-F0D5-4C8A-B230-5324516E54C8Q42970301-B031422A-8BDF-4EDC-A45C-3517D9F87D69Q42994549-0701FD4A-3F51-4A2D-8DD6-B475CC67503BQ43108044-EE97DFE9-D66E-4B5C-A259-72FB76F6A02EQ43252942-EAF94A32-21A5-4D1B-95C7-19372DAFC22B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Floridia
@ast
Marco Floridia
@en
Marco Floridia
@es
Marco Floridia
@nl
Marco Floridia
@sl
type
label
Marco Floridia
@ast
Marco Floridia
@en
Marco Floridia
@es
Marco Floridia
@nl
Marco Floridia
@sl
prefLabel
Marco Floridia
@ast
Marco Floridia
@en
Marco Floridia
@es
Marco Floridia
@nl
Marco Floridia
@sl
P1053
Q-6571-2017
P106
P21
P31
P3829
P496
0000-0003-3971-0141